Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00375674 · BASELINE

Baseline characteristics

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer · Source last updated 2018-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      309
    2. group Id
      BG001
      value
      306
    3. group Id
      BG002
      value
      615
    units
    Participants
groups
  1. description
    Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.
    id
    BG000
    title
    Sunitinib
  2. description
    Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.
    id
    BG001
    title
    Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.6
          value
          56.8
        2. group Id
          BG001
          spread
          10.6
          value
          57.9
        3. group Id
          BG002
          spread
          10.6
          value
          57.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
      title
      <=18 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          233
        2. group Id
          BG001
          value
          224
        3. group Id
          BG002
          value
          457
      title
      Between 18 and 65 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          82
        3. group Id
          BG002
          value
          158
      title
      >=65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          87
        2. group Id
          BG001
          value
          77
        3. group Id
          BG002
          value
          164
      title
      Female
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          222
        2. group Id
          BG001
          value
          229
        3. group Id
          BG002
          value
          451
      title
      Male
    param Type
    NUMBER
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
population Description
Intent to treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      309
    2. group Id
      BG001
      value
      306
    3. group Id
      BG002
      value
      615
    units
    Participants
groups
  1. description
    Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.
    id
    BG000
    title
    Sunitinib
  2. description
    Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.
    id
    BG001
    title
    Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.6
          value
          56.8
        2. group Id
          BG001
          spread
          10.6
          value
          57.9
        3. group Id
          BG002
          spread
          10.6
          value
          57.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
      title
      <=18 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          233
        2. group Id
          BG001
          value
          224
        3. group Id
          BG002
          value
          457
      title
      Between 18 and 65 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          82
        3. group Id
          BG002
          value
          158
      title
      >=65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          87
        2. group Id
          BG001
          value
          77
        3. group Id
          BG002
          value
          164
      title
      Female
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          222
        2. group Id
          BG001
          value
          229
        3. group Id
          BG002
          value
          451
      title
      Male
    param Type
    NUMBER
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
population Description
Intent to treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice